Mon Nov 03 12:20:00 UTC 2025: Here’s a summarized news article based on the provided text, focusing on the most impactful elements:

Headline: uniQure’s Huntington’s Disease Gene Therapy Faces FDA Uncertainty, BLA Timeline Clouded

LEXINGTON, Mass. and AMSTERDAM, Nov. 3, 2025 — uniQure (NASDAQ: QURE), a leading gene therapy company, announced today that its investigational gene therapy for Huntington’s disease, AMT-130, faces an uncertain path to FDA approval after a pre-Biologics License Application (BLA) meeting.

The FDA now appears to disagree that Phase I/II data versus an external control may be sufficient for a BLA, a shift from prior guidance. As a result, the timing of the BLA submission for AMT-130 is now unclear.

uniQure executives expressed surprise at the FDA’s feedback, stating it was a “drastic change” from previous communications suggesting that existing data could support a BLA under the Accelerated Approval pathway.

The company expects final meeting minutes within 30 days and will urgently engage with the FDA to determine the best path forward. They also plan parallel discussions with regulatory agencies in the European Union and United Kingdom. AMT-130 holds Breakthrough Therapy (Apr 2025) and RMAT (May 2024) designations.

The news raises questions about the future of AMT-130 in the U.S. and potentially impacts the timeline for bringing a much-needed treatment to patients suffering from Huntington’s disease.

Key Takeaways:

  • FDA Shift: The FDA has seemingly changed its stance on the data required for BLA approval of uniQure’s AMT-130.
  • BLA Uncertainty: The timing of the BLA submission is now unclear, impacting the timeline for potential U.S. approval.
  • Company Response: uniQure expresses surprise and disappointment and vows to work with the FDA to find a path forward.
  • Global Implications: The company will also engage with regulatory agencies in the EU and UK.

    Read More